The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
In This IssueFull Access

In This Issue

How Reports of Shootings Affect Views of the Mentally Ill and Gun Control

A national survey showed that more than 70% of all respondents favored banning gun sales to the seriously mentally ill, whereas support for restricting high-capacity magazines varied according to news accounts read just before the survey (figure). McGinty et al. (p. Original article: 494) report that baseline support for a ban of large magazines was 48%, whereas the rate among respondents who read a fictional story of a mass shooting by a mentally ill man using a large magazine was 57%, which rose to 69% when the account also mentioned legislation proposing such a ban. In their editorial, Friedman and Michels (p. Original article: 455) discuss issues raised by recent legislative efforts to link mental illness with gun violence.

Survey support for gun restrictions on the seriously mentally ill was uniformly high (McGinty et al., p. Original article: 494)

Prolonged Fatigue in Adolescents

Extended extreme fatigue with at least one associated symptom was identified in 3% of 10,123 adolescents in a representative U.S. sample. About half had the fatigue syndrome only, and about half also had a depressive or anxiety disorder. Lamers et al. (CME, p. Original article: 502) report that the rate of severe or very severe disability was nearly 60% in the adolescents with the fatigue syndrome only, but only 12% had received any health care for it. However, note Bleijenberg and Knoop in an editorial (p. Original article: 459), the natural course of chronic fatigue syndrome in adolescents is much more favorable than the course in adults.

Clinical Guidance: Libido Loss in Women With Schizophrenia

Sexual dysfunction is common in women with schizophrenia taking antipsychotics. Lifestyle changes may help those with obesity or diabetes, as these conditions are associated with antipsychotics and can cause sexual dysfunction. Antipsychotics that raise prolactin are most related to sexual problems, and lowering the dose or changing the hour of ingestion may help. Other suggestions by Seeman (p. Original article: 471) include adding a prolactin-lowering medication and switching to a prolactin-lowering antipsychotic; aripiprazole reliably decreases prolactin, and quetiapine does in some cases. Lower prolactin may lead to pregnancy, and therefore the clinician should discuss reproductive choices with the patient.

Clinical Guidance: Anorexia Nervosa Viewed as Habitual Behavior

Many patients with anorexia nervosa report that dieting helps them cope with negative affect, but once the behavior is paired with a desired outcome, it may become rewarding itself. This formulation of anorexia nervosa by Walsh (CME, p. Original article: 477) is consistent with findings that adolescent onset and shorter duration of illness are among the few factors associated with better outcome. Cognitive-behavioral therapy, interpersonal therapy, and antidepressants are ineffective, whereas interrupting the behavior and restoring normal weight are considered crucial. Younger patients often respond to family-based treatment, in which parents refeed the child to interrupt the dieting behavior. Patients with long-standing anorexia nervosa may be helped by adding habit-reversal techniques to current interventions.

Clinical Guidance: Maternal SSRIs Do Not Stunt Infant Growth

Infants of women who took selective serotonin reuptake inhibitor (SSRI) antidepressants during pregnancy did not differ from infants of unmedicated healthy women in weight, length, or head circumference during the first year of life. Infants of depressed women who did not take antidepressants during pregnancy likewise showed no difference in growth. The women who took SSRIs had more preterm births than the healthy women, and their babies were shorter at birth, but Wisner et al. (p. Original article: 485) found no difference at 2 weeks or afterward. These findings are reassuring, states Parry in an editorial (p. Original article: 453), because a lack of infant growth can have long-term medical and social consequences.